专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06750325B1 CD3 specific recombinant antibody 失效
标题翻译： CD3特异性重组抗体
公开(公告)号：US06750325B1
公开(公告)日：2004-06-15
申请号：US09348224
申请日：1999-07-06
申请人： Linda Kay Jolliffe , Robert Allan Zivin , John Robert Adair , Diljeet Singh Athwal
发明人： Linda Kay Jolliffe , Robert Allan Zivin , John Robert Adair , Diljeet Singh Athwal
IPC分类号： C12P2108
CPC分类号： C07K16/465 , A61K38/00 , C07K16/18 , C07K16/241 , C07K16/2803 , C07K16/2809 , C07K16/2812 , C07K16/461 , C07K2317/24 , C07K2319/00
摘要： The invention provides recombinant antibody molecules comprising antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and which have anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanized antibody and may be a chimeric or CDR-grafted antibody. A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. The recombinant, especially the humanized, anti-CD3 antibodies may be used for in vivo therapy or diagnosis.
摘要翻译：本发明提供包含衍生自供体抗CD3抗体的重链和/或轻链可变区的抗原结合区的重组抗体分子，例如。 OKT3，其具有抗CD3结合特异性，优选具有与OKT3相似的亲和力。重组抗体优选为人源化抗体，可为嵌合或CDR移植抗体。公开了一种用于制备CDR-移植的人源化抗体的方法，其中除了CDR的非人抗体之外，残基优选用于重链可变区的第23,24,49,71,73和78位，在第46位，48,58和71。重组体，特别是人源化抗CD3抗体可用于体内治疗或诊断。

2. 发明授权

US5929212A CD3 specific recombinant antibody 失效
标题翻译： CD3特异性重组抗体
公开(公告)号：US5929212A
公开(公告)日：1999-07-27
申请号：US116247
申请日：1993-09-03
申请人： Linda Kay Jolliffe , Robert Allan Zivin , John Robert Adair , Diljeet Singh Athwal
发明人： Linda Kay Jolliffe , Robert Allan Zivin , John Robert Adair , Diljeet Singh Athwal
IPC分类号： A61K39/395 , A61K20060101 , A61K38/00 , A61K49/00 , A61P37/00 , C07K14/435 , C07K14/52 , C07K14/525 , C07K14/725 , C07K16/00 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/42 , C07K16/46 , C07K19/00 , C12N20060101 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/00 , C12P21/02 , C12P21/08 , C12Q20060101 , C12R1/91 , G01N33/53 , G01N33/577 , C07H21/04
CPC分类号： C07K14/7051 , C07K16/18 , C07K16/241 , C07K16/2803 , C07K16/2809 , C07K16/2812 , C07K16/461 , C07K16/465 , A61K38/00 , C07K2317/24 , C07K2319/00 , C07K2319/02
摘要： The invention provides recombinant antibody molecules comprising antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and which have anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanized antibody and may be a chimeric or CDR-grafted antibody. A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's, non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. The recombinant, especially the humanized, anti-CD3 antibodies may used for in vivo therapy or diagnosis.
摘要翻译：本发明提供包含衍生自供体抗CD3抗体的重链和/或轻链可变区的抗原结合区的重组抗体分子，例如。 OKT3，其具有抗CD3结合特异性，优选具有与OKT3相似的亲和力。重组抗体优选为人源化抗体，可为嵌合或CDR移植抗体。公开了一种用于制备CDR-移植的人源化抗体的方法，其中除CDR之外，非人抗体残基优选用于重链可变区的第23,24,49,71,73和78位，轻链可变区的46,48,58和71。重组体，特别是人源化抗CD3抗体可用于体内治疗或诊断。

3. 发明授权

US07041459B2 Analyzing phosphorylated proteins 失效
公开(公告)号：US07041459B2
公开(公告)日：2006-05-09
申请号：US10153312
申请日：2002-05-21
申请人： Sharat Singh , Robert Allan Zivin
发明人： Sharat Singh , Robert Allan Zivin
IPC分类号： G01N33/53
CPC分类号： G01N33/6842 , G01N33/6803 , Y10S436/808
摘要： Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone phosphorylation. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and an IMAC resin for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of phosphorylation activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in phosphorylation of the target polypeptide. The interaction between the IMAC resin and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式